Mesentech makes bi-specific small-molecule therapeutics that are selective for both a tissue target and a molecular target. These conjugates deliver an active pharmaceutical agent selectively to target tissue thereby eliminating side effects caused by systemic exposure.
Mesentech was founded by Dr. Robert Young — who led teams that discovered SingulAir, Vioxx, Arcoxia, ondanacatib, among others while leading medicinal chemistry at Merck. Mesentech lead compound is MES1007, a bone-targeted prodrug of a prostaglandin mimetic that has the potential to reverse bone-loss caused by diseases such as Duchenne muscular dystrophy and osteoporosis. We are also leveraging the bi-specific drug conjugate technology to develop new drugs for hematological and gastrointestinal diseases.